Nutriband inc. announces $8.4m private placement

Nutriband is targeting a 505(b)(2) nda to the fda for marketing approval of aversa™ fentanyl in q1 2025 orlando, fl / accesswire / april 19, 2024 / nutriband inc. (nasdaq:ntrb)(nasdaq:ntrbw), a company engaged in the development of abuse deterrent pharmaceutical products announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 2,100,000 shares of common stock (the "shares"), at a purchase price of $4 per share of common stock; for each share of common stock purchased the investor receives a five-year warrant to purchase two shares of common stock. the exercise price of the warrants is $6.43 per share.
NTRB Ratings Summary
NTRB Quant Ranking